The symptoms are blurred vision, loss of contrast, alteration of color vision and spots on vision.
Bayer presented its innovative Aphlibercept molecule
It is estimated that 30 percent of diabetes patients have some degree of visual damage due to diabetic retinopathy, their most frequent complication being macular edema.
To reduce visual deterioration and the risk of blindness in Mexicans, Bayer presented the new therapeutic indications of its innovative Aphliberpt molecule, which has demonstrated vision improvement in five of the main diseases of the retina: diabetic macular edema, occlusion of occlusion ofThe central vein of the retina, occlusion of the venous branch of the retina, myopic neovascularization and macular degeneration related to age in its wet form.
The indication of Aphliberpt for diabetic macular edema takes on great relevance in our country, since diabetic retinopathy and its complications produce almost five percent of the 37 million blind people in the world, being essential to have treatments that contribute to improving the visual quality ofPatients with this eye disease, said Dr. Gabriela Lópezcaras, former president of the Mexican Retina Association.
Diabetic macular edema occurs when (derived from high glucose levels) the blood vesselThe visual function.
Diabetic macular edema can occur at any stage of retinopathy and is the most important cause of limitation and blindness, said Dr. Francisco Nava, medical manager of the Ophthalmology Area of the Pharmaceuticals Division of Bayer in Mexico.
The deterioration of vision related to diabetic macular edema can hinder everyday functions of those who suffer from it, such as reading, conducting or distinguishing colors, significantly affecting their quality of life and even causing blindness, warned the ophthalmologist.
The symptoms of diabetic macular edema include blurred vision, loss of contrast, alteration of color vision and spots on vision.However, these visual manifestations usually appear in advanced stages of the disease.
One of the advances in the management of diabetic macular edema is the use of medicines known as intravitreal antiangiogenic therapies, which currently represent the first line of treatment for this complication of diabetic retinopathy, since clinical studies have shown that it is more effective inReduce diabetic macular edema and improve the vision that corticosteroid therapy and laser photocoagulation, without the complications associated with previous treatments, said Dr. Juan Manuel Jiménez Sierra, a doctor assigned to the retinal and vitreous department of the Hospital of the Association for the Association for the Association forAvoid blindness in Mexico.
Within this therapeutic family, Aphlibercept, being the only treatment for diabetic macular edema that inhibits the action of two proteins involved in the formation and permanence of abnormal blood vesselwhich are responsible for promoting injuries in the macula that translate into a reduction in central vision.
“In addition to this, this drug has a greater permanence of intraocular activity, compared to other antiangiogenic ones in the market, which allows patients to prevent loss of vision, stabilize vision, and even improve their visual acuity with aLess number of treatment applications, ”he said.
